The vials containing an expensive, controversial drug for Alzheimer's disease are fixed in size, yet the amount required by patients varies widely. This issue alone could waste $605 million in ...

Biogen's Alzheimer's drug Aduhelm has made headlines during the past month for its controversial FDA approval and annual price list price of $56,000. But Medicare and other insurers will likely ...

Aduhelm is available as a liquid solution that comes in a vial. It’s given as an IV infusion (an injection into your vein over a period of time). It’s prepared and given by a healthcare ...

In Aduhelm's case, Bach says the waste could total $2 billion in annual revenues on unused drug left in vials. That's based on an assumption that the treatment will reach 500,000 patients per year ...

STAT has identified another 15 major, university-affiliated hospitals that aren’t offering the controversial new Alzheimer's drug Aduhelm.

Aduhelm's pathway to regulatory approval has not been without challenges. As part of the phase III process to obtain FDA approval, a medication must be proven effective in two similar clinical trials.

Biogen has announced it will give up ownership and halt sales of Aduhelm, an embattled Alzheimer's disease drug that was scrutinized following its 2021 approval.. Biogen said it terminated a ...

Both Aduhelm and Leqembi have price tags exceeding $25,000 a year, making access challenging. An FDA spokesperson said patients currently on Aduhelm can continue treatment until Nov. 1 and should ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

Drugmaker Biogen is pulling the plug on its controversial Alzheimer's drug Aduhelm, following disappointing sales. It had been expected to be a blockbuster product.

B iogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s ...

Aduhelm (aducanumab) is an Alzheimer's drug targeting amyloid-beta plaques in the brain to slow disease progression. It was approved amid controversy.